TRPV1 and dry eye syndrome: As previously described, L-carnitine is able to suppress TRPV1 activation (Figures 5A,B,C) and Ca2+ influx (Figures 5D,E,F), which makes this osmoprotectant relevant for possible use in a clinical setting (e.g., dry eye) (15, 94–96).